Clinical Trials
Braintumor Website

There are 30 trials:
Facility: Novartis Investigative Site
NCT Trial Name# of Centers

NCT01713946

  A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures
81

NCT01794793

  Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
66

NCT01708174

  A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)
58

NCT02310269

  Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease
55

NCT02060383

  Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
42

NCT02034110

  Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
41

NCT00958841

  Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
35

NCT02180217

  Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
33

NCT01582061

  An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease
21

NCT01673646

  Efficacy and Safety of Pasireotide LAR in Japanese Patients With Acromegaly or Pituitary Gigantism
18

NCT01324479

  Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
17

NCT01576666

  Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
17

NCT01677741

  A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects
17

NCT01934361

  Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
16

NCT02697734

  Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
16

NCT01132664

  Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab
15

NCT02124772

  Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
14

NCT02381886

  A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
11

NCT01125800

  A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
11

NCT01137682

  Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
8

NCT01283542

  Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.
8

NCT01870726

  Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma
7

NCT02575365

  Effect of Fingolimod on Neurodegeneration
6

NCT02336451

  A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
5

NCT01106508

  A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
5

NCT01374906

  Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
3

NCT02338609

  Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301
3

NCT01208831

  An East Asian Study of LDE225
1

NCT01331239

  Safety and Efficacy of LCI699 in Cushing's Disease Patients.
1

NCT01915303

  Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
1



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites